Please login to the form below

Not currently logged in
Email:
Password:

Biogen

This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.

Novartis forms coronavirus alliance with life sciences companies

Novartis forms coronavirus alliance with life sciences companies

information. Biogen has also committed $10m to support global response efforts to the COVID-19 outbreak, and a host of companies, including Gilead, Moderna, Pfizer and more are developing vaccines and

Latest news

  • J&J aims for US approval of MS drug ponesimod J&J aims for US approval of MS drug ponesimod

    A range of blockbuster therapies are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab). ... Although Novartis and Biogen have so far been able to defend their patents on

  • Novartis launches $20m COVID-19 response fund Novartis launches $20m COVID-19 response fund

    Biogen has also committed $10m to support global response efforts to the COVID-19 outbreak, and a host of companies, including Gilead, Moderna, Pfizer and more are developing vaccines and therapeutics

  • Biogen joins COVID-19 efforts with $10m support fund Biogen joins COVID-19 efforts with $10m support fund

    Funds will be used to address 'immediate critical needs'. Biogen has committed $10m in support of global response efforts and communities who have been affected by the COVID-19 pandemic. ... Biogen also said that it will be supporting the Massachusetts

  • UK officially moves into ‘delay’ phase of coronavirus plan UK officially moves into ‘delay’ phase of coronavirus plan

    Meanwhile, across the Atlantic in the US, an outbreak of the coronavirus is snowballing in Cambridge, Massachusetts after a number of employees from Biogen tested positive for the virus. ... As of Thursday, cases had increased to 108 in the state, of

  • Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

    Biogen has made another big investment play in Alzheimer’s disease, penning a $350m upfront agreement with gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part ... The licensing deal comes as Biogen prepares to file its

More from news
Approximately 120 fully matching, plus 305 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 2 fully matching, plus 43 partially matching documents found.

Latest appointments

More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.

Latest from PMHub

  • Article: Market access in Brazil

    In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde

  • Healthcircle Healthcircle

    Biogen. Chugai. Eisai. Helsinn. Ipsen. Johnson &Johnson. Lundbeck. Medtronic. Mentholatum. Novartis.

  • Attigo (part of the Mednet Group) Attigo (part of the Mednet Group)

    Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.

  • IGNIFI IGNIFI

    Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. Kyowa Kirin.

  • Wallace Health

    Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as

More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics